RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE

This is the author's accepted manuscript of an article published in *The Journal of Feline Medicine and Surgery.*

The final publication is available at SAGE Journals via <u>https://doi.org/10.1177/1098612X17727692</u>.

The full details of the published version of the article are as follows:

TITLE: Acceptance of home blood glucose monitoring by owners of recently diagnosed diabetic cats and impact on quality of life changes in cat and owner

AUTHORS: Katarina Hazuchova, Ruth Gostelow, Christopher Scudder, Yaiza Forcada, David B Church, and Stijn JM Niessen

JOURNAL TITLE: Journal of Feline Medicine and Surgery

PUBLICATION DATE: September 15, 2017 (online)

PUBLISHER: SAGE Publications

DOI: 10.1177/1098612X17727692



- 1 Acceptance of home blood glucose monitoring by owners of recently diagnosed diabetic cats, and
- 2 impact on quality of life changes in cat and owner
- 3
- 4 Katarina Hazuchova, Ruth Gostelow, Christopher Scudder, Yaiza Forcada, David B. Church, Stijn J.M.
- 5 Niessen
- 6
- 7 Diabetic Remission Clinic (www.facebook.com/RVC.Diabetic.Remission.Clinic), The Royal Veterinary
- 8 College, Department of Clinical Services and Science, Hawkshead Lane, Hatfield, Hertfordshire, United
- 9 Kingdom
- 10
- 11 Corresponding author:
- 12 Katarina Hazuchova DVM DipECVIM-CA MRCVS
- 13 Diabetic Remission Clinic
- 14 The Royal Veterinary College
- 15 Department of Clinical Science and Services
- 16 Hawkshead Lane
- 17 Hatfield, Hertfordshire
- 18 AL9 7TA
- 19 United Kingdom
- 20 Email: <u>khazuchova@rvc.ac.uk</u>
- 21 Telephone: +447709 845860
- 22
- 23 A part of this study was presented as an oral abstract presentation at the 25th ECVIM-CA annual congress in
- 24 2015 in Lisbon, Portugal.
- 25 Keywords
- 26 diabetes mellitus, cat, home monitoring, quality of life, glycaemic control, blood glucose, remission

27 Abstract

28 **Objectives**

This study aimed to evaluate the acceptance of home blood glucose monitoring (HBGM) by owners of recently diagnosed diabetic cats, and the impact of choosing HBGM on the quality of life (QoL) changes of cat and owner, in addition to glycaemic changes during 6 months' follow-up.

32 Methods

33 Owners of cats diagnosed with diabetes mellitus (DM) and treated with insulin for 6-20 weeks were divided 34 into a HBGM group and a non-HBGM group based on their ability and willingness to perform HBGM after 35 standardised instruction session. The HBGM acceptance level and reasons for acceptance failure were 36 documented; a questionnaire evaluated owners' experiences. For the following 6 months, changes in QoL, 37 measured using the validated DIAQoL-pet quantification tool, and changes in glycaemic control parameters (clinical signs, serum fructosamine, blood glucose curve average/minimal/maximal/pre-insulin blood glucose 38 39 [BG]) were compared between HBGM and non-HBGM groups at months 1, 3 and 6, as well as within the 40 groups between baseline and months 1, 3 and 6.

41 Results

Thirty-eight cats were enrolled; 28 (74%) entered the HBGM group. There was no significant difference between groups in overall DIAQoL-pet score or glycaemic control parameters at any time point apart from the maximal BG at month 6 (lower in the HBGM group). However, the DIAQoL-pet score, including indicators of owner worry about DM, worry about hypoglycaemia and costs, as well as glycaemic parameters, improved at all time-points within the HBGM group, but not within the non-HBGM group. Remission occurred in 9/28 (32%) HBGM group cats and 1/10 (10%) non-HBGM group cats (p=0.236).

48 Conclusions and Relevance

HBGM was adopted successfully by most diabetic cat owners. Despite the extra task, positive changes in
QoL-parameters occurred in the HBGM group and not in the non-HBGM group. Although no difference was
found in glycaemic control between HBGM and non-HBGM group during the 6 months' follow-up, significant
glycaemic improvements were documented in the HBGM group.

54 Introduction

55 The management of feline diabetes mellitus (DM) is complex and is facilitated by cat owners understanding 56 the disease and their active participation in treatment. These factors help achieve the main treatment goals, 57 which include resolution of clinical signs and avoidance of hypoglycaemia and diabetic complications.^{1,2} 58 However, the daily involvement in the management of their pets' diabetes can also be perceived as a 59 substantial burden by some owners.^{3,4} A tool called DIAQoL-pet has been developed and psychometrically validated to gualify and guantify the guality of life (QoL) of diabetic pets and their owners, allowing more 60 61 specific monitoring of this important aspect of feline diabetes, alongside more traditional glycaemic parameters.^{3,4} 62

63 Although not considered a main treatment goal,^{1,2} some diabetic cats enter diabetic remission. The highest 64 remission rates have been reported in cats where good glycaemic control has been established early in the 65 course of the disease.^{5,6} The role of home blood glucose monitoring (HBGM) in achieving early good 66 glycaemic control has been widely acknowledged and has been included in the latest guidelines for management of DM in cats.² In human medicine, self-monitoring of blood glucose (SMBG) has been an 67 68 integral part of management of humans with type 1 and insulin-treated type 2 diabetes for many decades.⁷ 69 However, although the recommendations for treatment of human diabetes emphasise the utility of SMBG to 70 assess individual responses to therapy and prevention of hypoglycaemia, concerns about the potential 71 impacts of SMBG on QoL, particularly in people with type 2 DM, have been raised.^{8,9} In veterinary medicine, 72 the difficulties pet owners might encounter and the reasons for reluctance to perform HBGM have been sporadically addressed in previous canine and feline studies.¹⁰⁻¹³ However, these reports were mostly 73 74 concerned with biological effects as outcome parameters and merely listed what owners perceived as 75 challenges and benefits of HBGM. A prospective assessment of the possible psychosocial impact of HBGM, 76 using an objective validated measure such as the DIAQoL-pet, in a substantial number of patients with a 77 longer-term follow-up is yet to be reported in veterinary medicine.

The main aim of this study was therefore to evaluate the acceptance of HBGM by cat owners and its impact on QoL changes in diabetic cats and their owners over a 6-month period using the previously validated QoL tool, DIAQoL-pet.³ A secondary aim was to assess the effect of HBGM on glycaemic changes over the same time period.

82

83 Materials and methods

84 Cats diagnosed with DM ≤5 months previously and treated with insulin for at least 6 weeks prior to enrolment 85 were recruited for the study between October 2013 and September 2015. The study was approved by the 86 institutional Clinical Research and Ethical Review Board and was performed under Home Office Licence no. 87 70/7393. The diagnosis of DM was made based on a combination of appropriate clinical signs (polyuria, 88 polydipsia, polyphagia, weight loss) and laboratory parameters (hyperglycaemia [blood glucose (BG) >15 89 mmol/L], glycosuria). Cats were excluded if they received short-acting systemic glucocorticoids in the previous 90 month, depot glucocorticoids in the previous 2 months or progestogens in the previous 6 months. Cats were 91 also excluded if they were diagnosed with diabetic ketoacidosis at initial evaluation, if they were diagnosed 92 and treated for hyperthyroidism (except for cats successfully treated with radioactive iodine or thyroidectomy) 93 or were diagnosed with severe disease that could increase the risk associated with study participation or 94 require long-term medication. All cats were screened for hypersomatotropism and if found positive (based on insulin-like growth factor 1 [IGF-1]>1000 ng/mL)¹⁴ were not included. 95

On initial presentation, a thorough history was taken and physical examination, including body weight (BW),
estimation of body condition score (BCS; 1-9/9)¹⁵ and percentage of body fat (% of BF)¹⁶, were performed.
The severity of each cat's clinical signs at trial recruitment was graded using the validated clinical scoring
system (Diabetic Clinical Score) shown in Table 1.¹⁷ Cat owners were also asked to complete the DIAQoL-pet
survey to assess the influence of DM and its treatment on QoL.³ The DIAQoL-pet generated an AverageWeighted Impact Score (AWIS) to reflect pet and owner QoL, with more negative values reflecting a more
negative impact of DM.^{3,4}

103 All cats underwent initial screening tests including complete blood count (CBC), plasma biochemistry, full 104 urinalysis (including urine culture), and serum fructosamine, total T4 (TT4), feline pancreatic lipase 105 immunoreactivity (fPLI), IGF-1 measurement, and abdominal ultrasound. A 24-hour blood glucose curve 106 (BGC) was performed on each cat after admission, using either a continuous glucose monitoring system for 107 the measurement of glucose in the subcutaneous interstitial fluid (Guardian REAL-Time system, Medtronic) or 108 serial BG measurements in capillary blood collected from the ear using a portable BG meter (AlphaTRAK[®] 2, 109 Zoetis). In the latter case, BG was measured every 2 hours or more frequently if hypoglycaemia (BG<3 110 mmol/L) occurred. All cats were then transitioned onto a longer-acting insulin type (recombinant human 111 protamine zinc insulin [PZIR; ProZinc, Boehringer Ingelheim] or synthetic insulin analogue glargine [Lantus, 112 Sanofi]) at an initial dose of 0.2-0.7 U/kg. Cats were fed a low carbohydrate, high protein diet (Purina Pro Plan DM, Nestle Purina PetCare; wet or dry, depending on cat's preference), which commenced at least 10 days
 prior to the enrolment visit.

115 At discharge from the hospital, all cats received comprehensive introduction to HBGM which took at least 30 116 minutes. Owners were shown how to obtain a blood drop using the marginal ear vein technique and they 117 practised the technique on their own cat with the clinician. Cat owners were also taught how to use the 118 glucometer for measurement and how to calibrate it. To generate data for a BGC, owners were asked to 119 measure BG every 2 hours over a 12-hours period, starting just before morning feeding and insulin injection, 120 and finishing just before evening feeding and insulin injection. Owners were asked to record the data and 121 send the results to the research clinic and describe any clinical signs of diabetes that occurred around the 122 time of the BGC. Owners were asked to perform a BCG at the 1-week and 2-, 4- and 5-month trial time-points, 123 and also 1-2 weeks after any insulin dose adjustments. If owners did not perform HBGM, it was requested that 124 these BGCs were performed at the cat's primary-care practice. Cats that entered diabetic remission were 125 initially monitored using spot blood glucose checks 2-4 times weekly, but spot blood glucose measurements 126 were not otherwise routinely requested for monitoring.

Re-examinations at the research clinic were performed 2 weeks, 1 month, 3 and 6 months after joining the trial. At these time points, a full history and physical examination, serum fructosamine measurement, diabetic clinical score (DCS), and a 24-hour BGC were performed in all cats. Owners were also asked to complete the DIAQoL-pet survey. Additional monthly to bimonthly re-examinations took place at the referring veterinary practices, depending on the needs of individual cats. During the study, insulin dose was adjusted according to a single, nadir-led protocol, based on BGC results.¹⁷ Diabetic remission was defined as not requiring insulin for more than 4 weeks.

Owners were considered to have successfully adopted HBGM ("HBGM group") if they had performed a minimum of 2 BGCs at home within the first 3 months of enrolment. The remaining owners and their cats were included in the "non-HBGM group". This arbitrary cut-off of 2 BGCs was chosen, since the investigators explicitly did not want to include owners into the HBGM group if they had successfully performed one curve, though decided against further testing as a result of this experience.

139 At the end of the study period, owners were contacted by email and/or telephone and asked to complete a

140 questionnaire to describe their experiences with HBGM. The owners of cats included in the HBGM group were

141 asked about their general opinions of HBGM (e.g. if their lives were restricted by HBGM;

advantages/disadvantages of HBGM), the technique used for generating the BGCs, and difficulties they

encountered during HBGM (Supplement 1). The owners of cats in the non-HBGM group were asked why they
decided not to perform HBGM, or, if they performed some monitoring but then discontinued, why they
discontinued (Supplement 2).

146

147 Statistical analysis

148 The data were tested for normality where appropriate (Shapiro-Wilks test). Signalment, BW, BCS, % of BF, 149 fPLI, total number of BGCs performed during the study period, the time on insulin prior to enrolment, insulin 150 type choice (PZIR vs. glargine) and the insulin dose at enrolment were compared between cats in the HBGM-151 and non-HBGM group using Mann-Whitney and Chi-Square tests, as appropriate. To evaluate the impact of 152 HBGM on QoL changes in diabetic cats and owners, total DIAQoL-pet score and individual item-weighted 153 impact scores (IWIS) for specific questions (Table 2) were compared between HBGM- and non-HBGM groups 154 at enrolment and 1, 3 and 6 months after joining the trial. Similarly, DCS, twice-daily insulin dose and 155 parameters of glycaemic control (serum fructosamine, average BG, average pre-insulin BG, minimal and 156 maximal BG) were compared between the HBGM- and non-HBGM group at the same time points. Remission 157 rate between groups (HBGM- vs. non-HBGM group) and the effect of the insulin type used (PZIR vs. glargine) 158 on whether owners achieved HBGM, were compared using Chi-Square tests.

DIAQoL-pet score, IWIS for specific questions (as above), DCS, insulin dose and parameters of glycaemic
 control (as above) were compared within each group to assess changes in QoL and glycaemic control over
 time. Wilcoxon Signed Ranks test were used to compare values at months 1, 3 and 6 to baseline (enrolment)
 values.

Statistical analysis was performed using commercially available statistical software (SPSS version 22, IBMStatistics).

165

166 Results

167 Sixty-three cats were initially screened prior to enrolment in the 6-month trial and 46 cats were enrolled.

168 Reasons for exclusion of the 17 cats were as follows: neoplastic disease/mass lesion (n=4); probable

- hypersomatotropism (on the basis of IGF-1>1000 ng/mL; n=3); excessively fearful or aggressive cats (n=3);
- 170 cats already non-insulin dependent based on an in-hospital BGC (n=2); hyperthyroidism (n=1);
- 171 gastrointestinal disease (n=1); clinical signs suggestive of a forebrain disease (n=1); hypertrophic

cardiomyopathy with congestive heart failure (n=1); and cat owners declining study enrolment due to timeconstraints (n=1).

Among the 46 cats enrolled in the 6-month trial, 8 were already performing HBGM, leaving 38 cats for study inclusion. Owners of 28 cats (74%) were able to perform HBGM (HBGM group). The remaining 10 cats (26%) were included in the non-HBGM group.

There was no significant difference in the signalment, BW, BCS, % of BF, fPLI, time on insulin, insulin dose prior to enrolment, choice of insulin (PZIR vs glargine) between cats in the HBGM- and non-HBGM groups (Table 3). In the non-HBGM group, 90% cats (n=9) were male neutered compared to 46% (n=13) in the HBGM group (p=0.025).

Cats in the HBGM group had a median of 5 (range 2-10) BGCs performed at home, while cats in the non-HBGM had a median of 2.5 (range 1-7) BGCs performed at their primary veterinary practices during the 6months follow-up period. Each cat had additional 4 (range 2-4) BGCs performed at the research clinic during the same time period. The total number of BGCs (including curves performed at home, at the primary veterinary practices and at the research clinic) was not significantly different between the HBGM and non-HBGM group (p=0.082).

187 There was no difference between the HBGM- and non-HBGM group in regard to the total DIAQoL-pet score, 188 scores for specific questions, DCS, insulin dose, or parameters of glycaemic control at any time point during 189 the study, except for maximal BG at month 6, which was lower in the HBGM group (p=0.03; data shown in 190 Supplement 3) (Figures 1-3, Table 3, Supplement 3). Total DIAQoL-pet score was significantly improved at 191 months 1, 3 and 6 compared to baseline in the HBGM group but not in the non-HBGM group (Figure 1, Table 192 4). There were significant decreases in scores (and therefore positive impact) for general worry about 193 diabetes ("worry"; months 1, 3 and 6) and worry about hypoglycaemia in particular ("worry hypo"; months 3 194 and 6), and worry about costs (months 3 and 6) in the HBGM group. There were also significant decreases in 195 scores (indicating positive impact) for "restriction of owners' activities" and "work restrictions" (month 6) in the 196 HBGM group (Table 4). Overall, the scores for 6 of 9 specifically examined QoL areas had improved at month 197 6 compared to baseline in the HBGM group (Table 4) but not in the non-HBGM group (Supplement 4). There 198 were also significant reductions (i.e. improvements) in DCS, insulin dose and most parameters of glycaemic 199 control (fructosamine, average BG, average pre-insulin BG, minimal/maximal BG) at months 1, 3 and 6 200 compared to baseline in the HBGM group (Figures 2 and 3, Table 5), except for minimal BG at months 3 and 201 6. In the non-HBGM group, DCS also decreased at months 1, 3 and 6 compared to baseline (p<0.05).

Regarding insulin dose and parameters of glycaemic control in this group, only average pre-insulin BG at
month 6 and maximal BG at month 1 were significantly different (lower; p<0.05) from baseline (Supplement 5).
Diabetic remission occurred in 9/28 (32%) cats in the HBGM- and 1/10 (10%) cats in the non-HBGM group
(p=0.236).

206 Nineteen (68%) questionnaires were completed by owners of cats in the HBGM group. Ten of the 19 (53%) 207 owners performed >10 BGCs and 17/19 (89%) found HBGM "straightforward" or "mostly straightforward" to 208 perform; 2/19 (11%) respondents described it as "difficult". Technical difficulties (pricking the ear, obtaining 209 sufficient blood) were the most common challenges reported by 10/19 (53%) owners, followed by finding time 210 to perform HBGM (n=6/19; 32%), and gaining confidence (n=5/19; 26%). Ten of the 19 (53%) respondents felt 211 that their lives were not at all/not really restricted by HBGM, while 6/19 (32%) and 4/19 (21%) reported mild or 212 moderate restriction, respectively. Most owners mentioned several advantages of HBGM; not having to take 213 their cat to the veterinarian (n=16/19; 84%) or leave the cat at the practice (n=11/19; 58%) were the most 214 commonly reported. A summary of the advantages and disadvantages of HBGM, and a description of the 215 technique and difficulties encountered during HBGM, can be found in Table 6. Of cats in the HBGM group that 216 were alive at the time of writing, all owners were still performing HBGM.

Three of 10 questionnaires in the non-HBGM group were completed. Two owners managed to perform a few spot blood glucose measurements but not a whole curve; one owner tried performing curves but did not succeed. The reasons for discontinuing HBGM were stated as lack of assistance (n=2); a perception that the cat was anxious (n=3); difficulties obtaining a blood drop (n=2) or using a glucometer (n=2); and the perception that he/she was hurting the cat (n=1). Despite not being successful, one owner expressed a desire to try HBGM again, while the other two would "probably not"/"not" try it again.

223

224 Discussion

The main aim of this study was to determine the acceptance, and especially also the impact of HBGM on the QoL of diabetic cats and their owners. Although no significant difference in the overall QoL assessed by the DIAQoL-pet tool was found between the HBGM and non-HBGM group during the 6-months' study period, the overall QoL scores improved at all post-enrolment time-points in the HBGM group and not in the non-HBGM group. This suggests a possible positive impact of HBGM. The acceptance of HBGM by the owners of diabetic cats was high, with approximately 3 out of 4 successfully adopting HBGM. This proportion is similar or higher than in previous studies evaluating HBGM in diabetic cats.^{11,12} Importantly, 89% of those performing

232 HBGM found it "straightforward" or "mostly straightforward" and all questionnaire-respondents in the HBGM 233 group would recommend HBGM to all or at least some owners of diabetic cats. Based on the questionnaire 234 results, for owners practising HBGM, the benefits clearly outweighed any disadvantages. Notably, about half 235 the owners in the HBGM group stated that they did not feel their lives were restricted by HBGM. This agreed 236 with the results of the DIAQoL-pet assessment, indicating improvement of the overall QoL in the group 237 performing HBGM. Further, owners practicing HBGM reported significantly less worry about their cat's diabetes in general, and particularly about hypoglycaemia, compared to before the trial. This might be due to 238 239 feeling more in control because of the ability to check blood glucose at home, as has been previously 240 reported.¹¹ The scores of specific questions about possible restriction of owners' lives ("restrict your activities", 241 "social life", "working life") did not reveal negative effects associated with HBGM compared with the non-242 HBGM group. The item "costs" also improved over time in the HBGM group, but not in the non-HBGM group, 243 possibly reflecting cost savings because glycaemic checks were performed at home rather than at the 244 veterinary clinic.

245 The psychometrically validated DIAQoL-pet tool was used to objectively evaluate QoL in diabetic cats and 246 their owners. Although other factors might have contributed to the score, successful adoption of HBGM was 247 the major difference in the diabetes management after enrolment on the study. It is therefore likely that any 248 negative impact HBGM might have had on the QoL would have been reflected in deterioration of the total 249 DIAQoL-pet score or in the scores for the specific questions mentioned above. Since an improvement in 250 DIAQoL-pet score occurred, HBGM was considered to most likely have a positive effect on QoL, rather than 251 imposing an additional burden. In fact, HBGM group owners reported an improvement in impact on DIAQoLpet factors relating to life and work restrictions once the trial had started. This improvement was not 252 253 documented in the non-HBGM group.

254 Although improvement in QoL was documented in the HBGM group and not in the non-HBGM- group over time, the QoL scores were not different between these 2 groups at any time-point in the study. This lack of 255 256 statistically significant difference might have several reasons. Firstly, the non-HBGM group was smaller than 257 the HBGM group; secondly, the trial design resulted in cat owners essentially self-selecting group 258 assignments; thirdly, the HBGM group was not absolutely homogenous in terms of the frequency and intensity 259 of performing HBGM. However, the total number of BGCs was not significantly different between the HBGM 260 and non-HBGM group. Finally, lack of randomisation and owners' self-assignment to the groups might allow 261 for owner- or pet-related characteristics, intrinsic to the decision to accept or decline HBGM, to confound

262 treatment outcomes. For instance, if HBGM group owners were more motivated to do everything possible to 263 control their cat's diabetes, better treatment outcomes might be expected in that group. Nevertheless, owners 264 in both groups were prepared to follow the other aspects of the clinical trial, which included regular visits to the 265 research clinic, indicating that even the owners in the non-HBGM group were committed to the care of their 266 diabetic cat. Additionally, assigning owners to one of the two groups, and thus forcing some of them to accept 267 HBGM, would not be feasible or ethical. On the basis of direct comparison of QoL and glycaemic parameters, 268 the two groups were very similar at enrolment, further strengthening the validity of the comparisons drawn. 269 We used a questionnaire to assess the cat owners' experiences with the HBGM. Although closed-ended 270 questions offering fixed answer(s) were used, the option "other" was included in most of the questions, to 271 enable owners to provide additional free text information. Using open-ended questions might have been more 272 suitable to assess the owners' opinions on some issues (e.g. advantages/disadvantages of HBGM) without 273 introducing bias. However, using open-ended questions is also associated with higher risk of larger item non-274 response or invalid answers, resulting in missing data.¹⁸ Therefore, we compromised by including the option 275 "other".

276 The maximal BG at month 6 was significantly lower in the HBGM group compared to the non-HBGM group. 277 Additionally, in the HBGM-group, all glycaemic control parameters (except for minimal BG at months 3 and 6) 278 decreased significantly compared to enrolment values. In contrast, in the non-HBGM group, improvement in 279 only 2 glycaemic control parameters (maximal BG at month 1 and average BG at month 6) was identified, and 280 there was no consistent pattern for the remaining parameters. Nevertheless, it should also be emphasised 281 that when performing a direct comparison between cats in the HBGM- and non-HBGM group, a statistical 282 significant difference was not shown at any time point during the study. Superior glycaemic control has been 283 linked with higher remission rates.¹⁹ Also, HBGM was an essential part of management in studies reporting 284 the highest remission rates.^{5,6} Interestingly, 9/28 (32%) cats in the HBGM group underwent diabetic remission, 285 but this occurred in only 1/10 (10%) cats in the non-HBGM group. However, the difference between groups in 286 remission rates was not statistically significant. Large randomised prospective studies are recommended to 287 further investigate the impact of HBGM on remission rates.

Finally, random assignment of owners and cats to equally-sized HBGM- and non-HBGM groups might have yielded superior results in this respect. Given the importance of HBGM suggested in previous studies,^{5,6} our research group, guided by our ethical committee, considered that it would be inappropriate to not actively offer HBGM to owners as part of best clinical practice. Conversely, forcing owners, who could not or did not want to 292 perform HBGM to enrol in the HBGM group would not be feasible or ethical either. Although this approach 293 might have introduced selection bias into the study, this situation is more likely to reflect the "real-life" 294 circumstances when, ideally, all owners should be able to make an informed choice about the protocol they 295 use to manage their cat's diabetes.

296

297 Conclusions

Most (n=28/38; 74%) owners of diabetic cats were able to perform HBGM and the majority (n=17/19; 89%) 298 299 considered it to be (mostly) straightforward. Overall QoL evaluated by the validated psychometric tool 300 DIAQoL-pet improved significantly in cats/ owners choosing to perform HBGM. Specifically of interest was an 301 owner-reported decrease in worry about the diabetes and particularly hypoglycaemia in the HBGM group, 302 which did not occur in the non-HBGM group. This study adds to the body of peer-reviewed evidence that 303 suggests HBGM is a practical monitoring tool for many owners of diabetic cats and suggests it is associated 304 with a positive impact on QoL in both the diabetic cat and the owner. Further studies are warranted to assess 305 its possible positive impact on glycaemic control.

306

307 Acknowledgements

308 The authors thank all diabetic cats and their owners who participated in this research.

309

310 Funding

This research was supported by funding from Zoetis. The glucometers and home blood glucose monitoring disposables were provided by Zoetis. The research clinic also receives funding from Boehringer Ingelheim and Nestlé Purina PetCare.

314

315 **Conflicts of interest**

This research was supported by Zoetis, which sells glucometers for use in dogs and cats. However, under the

317 Royal Veterinary College's Code of Research Conduct, the authors performed the research entirely

- independently, and did not allow external influence over the generation, reporting or interpretation of the
- 319 results reported in this paper.
- 320

321 Supplementary information:

- 322 Supplement 1 Questionnaire about owner's experience with home blood glucose monitoring HBGM-group.
- 323 Supplement 2 Questionnaire about owner's experience with home blood glucose monitoring non-HBGM-

324 group.

- 325 Supplement 3 Supplementary material to Table 1.
- 326 Supplement 4 Comparison of DIAQoL-pet at different time points within the non-HBGM group.
- 327 Supplement 5 Comparison of parameters of glycaemic control at different time points within the non-HBGM328 group.
- 329

330 References

- Rucinsky R, Cook A, Haley S, et al. AAHA Diabetes management guidelines for dogs and cats. *J Am Anim Hosp Assoc* 2010; 46: 215-224.
- Sparkes AH, Cannon M, Church D, et al. ISFM Consensus guidelines on the practical management of
 diabetes mellitus in cats. *J Fel Med Surg* 2015; 17: 235-250.
- Niessen SJM, Powney S, Guitian J, et al. Evaluation of a quality-of-life tool for cats with diabetes
 mellitus. *J Vet Intern Med* 2010; 24: 1098-1105.
- Niessen SJM, Powney S, Guitian J, et al. Evaluation of a quality-of-life tool for dogs with diabetes
 mellitus. *J Vet Intern Med* 2012; 26: 953-961.
- Roomp K, Rand J. Intensive blood glucose control is safe and effective in diabetic cats using home
 monitoring and treatment with glargine. *J Fel Med Surg* 2009; 11: 668-682.
- Roomp K, Rand J. Evaluation of detemir in diabetic cats managed with a protocol for intensive blood
 glucose control. *J Fel Med Surg* 2012; 14: 566- 572.
- 344 7. Standards of medical care in diabetes 2015. *Diabetes Care* 2015; 38 (Suppl.1): S1-S94.
- Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal
 qualitative study of patients' perspectives. *BMJ* 2007; 335: 493.
- Hortensius J, Kars MC, Wierenga WS, et al. Perspectives of patients with type 1 or insulin-treated
 type 2 diabetes on self-monitoring of blood glucose: a qualitative study. *BMC Public Health* 2012; 12:
 167.
- Casella M, Wess G, Hässig M, Reusch CE. Home monitoring of blood glucose concentration by
 owners of diabetic dogs. *J Small Anim Pract* 2003; 44: 298-305.

- 352 11. Kley S, Casella M, Reusch CE. Evaluation of long-term home monitoring of blood glucose
 353 concentrations in cats with diabetes mellitus: 26 cases (1999-2002). *J Am Vet Med Assoc* 2004; 225:
 354 261-266.
- 355 12. Casella M, Hässig M, Reusch CE. Home-monitoring of blood glucose in cats with diabetes mellitus:
 association over a 4-month period. *J Fel Med Surg* 2005; 7: 163-171.
- 357 13. Van de Maele I, Rogier N, Daminet S. Retrospective study of owners' perception on home monitoring
 358 of blood glucose in diabetic dogs and cats. *Can Vet J* 2005; 46: 718-723.
- 359 14. Niessen SJ, Petrie G, Gaudiano F, et al. Feline acromegaly: an underdiagnosed endocrinopathy? J
 360 *Vet Intern Med.* 2007; 21: 899-905.
- 361 15. Laflamme D. Development and validation of a body condition score system for cats: A clinical tool.
 362 *Feline Pract* 1997; 25: 13-18.
- 363 16. Butterwick R. How fat is that cat? *J Fel Med Surg* 2000; 2: 91-94.
- 364 17. Gostelow R, Hazuchova K, Scudder C, et al. Prospective evaluation of a protocol for transitioning
 365 porcine lente insulin-treated diabetic cats to human recombinant protamine zinc insulin. *J Fel Med* 366 *Surg*. Epub ahead of print 15 March 2017. DOI: 10.1177/1098612X17697482.
- Reja U, Manfreda KL, Hlebec V, Vehovar V. Open-ended vs close-ended questions in web
 questionnaires. In: Ferligoj A, Mrvar A, eds. *Developments in Applied Statistics*. Ljubljana, Slovenia:
 FDV; 2003. Metodoloski Zvezki 19.
- 370 19. Marshall RD, Rand JS, Morton JM. Treatment of newly diagnosed diabetic cats with glargine insulin
 371 improves glycaemic control and results in higher probability of remission than protamine zinc and
 372 lente insulins. *J Fel Med Surg* 2011; 11: 683-691.
- 373
- 374

Table 1. The validated Diabetic Clinical Score (DCS) used to grade the severity of diabetes-associated clinical

376 signs in participating cats

Clinical Sign Boing Secred	Severity	Assigned
Clinical Sign Being Scored	Seventy	Score
Unintended weight loss over the past 2	None, or weight gain	0
months	Mild (<5% loss)	1
(Assessed using bodyweight records or	Moderate (5-10% loss)	2
measurements)	Severe (>10% loss)	3
Increased drinking and/or urination	None	0
(Assessed by questioning owner)	Mild – some increase noted	1
	Moderate – increased filling of water bowl	2
	Severe – constantly seen to drink	3
Increased appetite	Normal or decreased appetite	0
(Assessed by questioning owner)	Mild – finishes food eagerly	1
	Moderate – finishes food eagerly and begs	2
	for more	_
	Severe – obsessed with food	3
Decreased activity/ attitude	Normal or increased activity	0
(Assessed by questioning owner)	Mild – slightly less active	1
	Moderate – certainly less active	2
	Severe – mainly lying around	3
	Total score	/12

Table 2. Overview of questions (items) of the DIAQoL-pet survey³ pertinent with regards to home blood glucose monitoring (HBGM). Each item was scored according to frequency at which it impacted on owner's and pets' lives (all the time [3], often [2], occasionally [1], never [0]) and how important the item was in the individual owner's and pet's lives (very important [4], important [3], moderately important [2], low importance [1], not at all important [0]). Item-weighted impact score (IWIS) was calculated for each item by multiplying

- 384 frequency and importance ratings for each question.

Abbreviation	Question (item)
More control	Do you ever feel you want to take more control of the diabetes on your own,
	without the help of vets and other people?
Hypoglycaemia	Does your pet ever show signs of a low blood sugar? (eg, wobbliness, collapse)
Worry hypo	Do you ever feel worried about your pet suffering from an episode of low blood
	glucose?
Costs	Do you ever worry about how much money your pet's diabetes costs you and
	your family?
Worry	Do you ever worry about your pet's diabetes?
Restrict your	Do you ever find the diabetes of your pet restricts or limits what you are doing or
activities	what you want to do, like going on holidays, away on weekends, away for the
	day/night, working?
Social life	Do you ever find you need to fit your pet's diabetes into your social life? (eg,
	carrying needles, food, insulin, providing food on time)
Working life	Do you ever find you need to fit your pet's diabetes into your working life? (eg,
	having to make special arrangements when you need to work late or need to
	start working earlier)
Special bond	Do you feel you have a more special bond with your pet now that you are
	managing his/her diabetes?

Table 3. Comparison of the demographic data, DIAQoL-pet score (quality of life tool) and parameters of

387 glycaemic control (DCS – diabetic clinical score; serum fructosamine; average blood glucose based on blood

- 388 glucose curve) between the HBGM (home blood glucose monitoring)- and non-HBGM group at enrolment,
- 389 months 1, 3 and 6.

Parameter	HBGM group	Non-HBGM group	p-value
Number of cats	28	10	
Age (years) (median, range)	12.05 (4-17.2)	9.5 (7-15.5)	0.076
Age (months) (median, range)	144.7	113.3	0.085
	(48.4-206.8)	(84.1-185.4)	
Breed			1.00
- Domestic Shorthair+Longhair	25	9	
- Other breed			
	3	1	
Gender			0.025
- female spayed	15	1	
- male neutered	13	9	
BW (kg) (median, range)	4.4 (2.8-8.3)	5.1 (3-6.9)	0.226
BCS (median, range)	5 (1-8)	5 (3-8)	0.723
% BF (median, range)	22.8 (2.11-42.5)	21.6 (16.6-32.4)	0.921
fPLI (ug/L) (median, range)	3.55 (0.5-58.0)	3.8 (0.5-50)	0.715
Time on insulin prior to enrolment	59 (36-150)	60.5 (44-108)	0.947
(days)			
Insulin dose prior to enrolment (U/cat)	2 (1-5)	2.5 (1-6)	0.893
Insulin dose prior to enrolment (U/kg	0.51 (0.22-1.32)	0.54 (0.24-1.16)	0.691
BW)			
Insulin type subsequently used	14 ProZinc/	5 ProZinc /	1.00
	14 Glargine	5 Glargine	
DIAQoL-pet month 0	-1.52	-1.31	0.390
(median, range)	(-4.450.31)	(-5.340.1)	

-1.12	-1.21	0.940
(-3.69 - +0.28)	(-3.590.3)	
-0.95	-0.76	0.603
(-4.83 - +0.38)	(-1.590.3)	
-0.45	-0.9	0.352
(-3.14 - +0.14)	(-2.280.3)	
476.5 (59-715)	431.5 (168-715)	0.703
380 (232-572)	398.5(233-575)	0.473
302 (215-606)	349 (241-560)	0.406
307 (215-636)	351 (248-561)	0.429
3.5 (0-11)	3.5 (0-9)	0.651
1 (0-5)	1.5 (0-5)	0.750
0 (0-6)	1 (0-4)	0.118
0 (0-6)	1 (0-2)	0.417
14.2	12.9	0.829
(7.9-21.7)	(7.7-22.2)	
10.6	10.5	0.572
(4.1-21.5)	(4-19.2)	
10.85	14.35	0.234
(4.1-21.4)	(7.6-19.7)	
9.95	13.75	0.146
(3.4-19.9)	(7.7-19.3)	
9/28	1/10	0.236
70 (40-130)	45 (n/a)	n/a
	(-3.69 - +0.28) -0.95 $(-4.83 - +0.38)$ -0.45 $(-3.14 - +0.14)$ $476.5 (59-715)$ $380 (232-572)$ $302 (215-606)$ $307 (215-636)$ $307 (215-636)$ $307 (215-636)$ $307 (215-636)$ $3.5 (0-11)$ $1 (0-5)$ $0 (0-6)$ $0 (0-6)$ 14.2 $(7.9-21.7)$ 10.6 $(4.1-21.5)$ 10.85 $(4.1-21.5)$ 10.85 $(4.1-21.4)$ 9.95 $(3.4-19.9)$ $9/28$	(-3.69 + 0.28) $(-3.59 - 0.3)$ -0.95 -0.76 $(-4.83 - +0.38)$ $(-1.59 - 0.3)$ -0.45 -0.9 $(-3.14 - +0.14)$ $(-2.28 - 0.3)$ $476.5 (59-715)$ $431.5 (168-715)$ $380 (232-572)$ $398.5 (233-575)$ $302 (215-606)$ $349 (241-560)$ $307 (215-636)$ $351 (248-561)$ $307 (215-636)$ $351 (248-561)$ $3.5 (0-11)$ $3.5 (0-9)$ $1 (0-5)$ $1.5 (0-5)$ $0 (0-6)$ $1 (0-4)$ $0 (0-6)$ $1 (0-2)$ 14.2 12.9 $(7.9-21.7)$ $(7.7-22.2)$ 10.6 10.5 $(4.1-21.5)$ $(4-19.2)$ 10.85 14.35 $(4.1-21.4)$ $(7.6-19.7)$ 9.95 13.75 $(3.4-19.9)$ $(7.7-19.3)$ $9/28$ $1/10$

390

BW – body weight; BCS – body condition score (1-9/9)¹⁵; % BF – percentage of body fat¹⁶; BG – blood

391 glucose; n/a – not applicable 392 **Table 4.** Comparison of DIAQoL-pet (quality-of-life tool), including specific questions (see below), between

enrolment and months 1, 3 and 6 within the HBGM group.

Parameter	Enrolment	Month 1	Month 3	Month 6
	(month 0)			
DIAQoL-pet	-1.52	-1.12 *	-0.95 **	-0.45 ****
(median, range)	(-4.450.31)	(-3.69 - +0.28)	(-4.83 - +0.38)	(-3.14 - +0.14)
"owner wanting	0.00	0.00	0.00	0.00 *
more control"	(-12.00 – 0.00)	(-8.00 – 0.00)	(-6.00 – 0.00)	(-4.00 – 0.00)
(median, range)				
"hypo"	0.00	0.00	0.00	0.00
(median, range)	(-4.00 - 0.00)	(-3.00 – 0.00)	(-8.00 – 0.00)	(-4.00 – 0.00)
"worry hypo"	-3.00	-3.00	-1.00 **	0.00 ***
(median, range)	(-8.00 - 0.00)	(-9.00 – 0.00)	(-12.00 – 0.00)	(-8.00 – 0.00)
"costs"	-4.00	-2.00	-1.00 *	0.00 ***
(median, range)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)
"worry"	-4.00	-2.00 *	-3.00 **	-2.00 **
(median, range)	(-12.001.00)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)
"restrict your	-3.00	-2.00	-2.00	0.00 **
activities" (median,	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-9.00 – 0.00)
range)				
"social life"	-3.00	-2.00	-1.00	0.00
(median, range)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-9.00 – 0.00)
"working life"	-2.00	0.00	-2.00	0.00 *
(median, range)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)	(-12.00 – 0.00)
"special bond"	2.00	2.00	1.00	2.00
(median, range)	(0.00 – 12.00)	(0.00 – 12.00)	(0.00 – 12.00)	(0.00 – 12.00)

394

* The value is significantly different from enrolment (month 0) at a level of significance p<0.05

³⁹⁵ ** The value is significantly different from enrolment (month 0) at a level of significance p<0.01

396 *** The value is significantly different from enrolment (month 0) at a level of significance p<0.001

398

Table 5. Comparison of parameters of glycaemic control at different time points within the HBGM group.

Parameter	Enrolment	Month 1	Month 3	Month 6
	(month 0)			
DCS (median, range)	3.5	1 ****	0 ****	0 ***
	(0-11)	(0-5)	(0-6)	(0-6)
Serum fructosamine	476.5	380 **	302 **	307 ***
(umol/L) (median, range)	(59-715)	(232-572)	(215-606)	(215-636)
Insulin dose (U/cat)	2	2 *	2 *	1.5 *
(median, range)	(1-5)	(0.25-5.5)	(0-5)	(0-6.5)
Insulin dose (U/kg BW)	0.51	0.45 *	0.41 *	0.32 **
(median, range)	(0.22-1.32)	(0.06-1.36)	(0-1.08)	(0-1.65)
Average BG (mmol/L)	14.2	10.6 ***	10.85 ***	9.95 **
(median, range)	(7.9-21.7)	(4.1-21.5)	(4.1-21.4)	(3.4-19.9)
Average pre-insulin BG	18.2	11.75 ****	11.45 **	13.1 *
(mmol/L)	(8.3-23.3)	(5.5-20.6)	(3.6-22.2)	(6.7-19.9)
(median, range)				
Minimal BG (mmol/L)	6.55	3.5 *	5.7	4.9
(median, range)	(2.2-18.4)	(2.2-18.4)	(2.2-17.1)	(2.2-12.8)
Maximal BG (mmol/L)	22.2	20.2 *	19.5 **	14.9 ***
(median, range)	(13.2-22.2)	(8.9-22.2)	(6.3-22.2)	(5.4-22.2)

400

DCS – diabetic clinical; BG – blood glucose

* The value is significantly different from enrolment (month 0) at a level of significance p<0.05
** The value is significantly different from enrolment (month 0) at a level of significance p<0.01

403 *** The value is significantly different from enrolment (month 0) at a level of significance p<0.001

404 **** The value is significantly different from enrolment (month 0) at a level of significance p<0.0001

- 406 **Table 6.** Summary of advantages and disadvantages of home blood glucose monitoring (HBGM) as well as
- 407 description of the technique and difficulties encountered during HMBG. Number and percentage of
- 408 respondents (of 19 returned questionnaires) are given in brackets after the item.

Advantages of HMBG:

- not having to take their cat to the veterinarian or leave the cat at the practice (n=16; 84%)
- owner feeling to have more control over their cat's diabetes (n=13; 68%)
- owner feeling their cat's diabetes is better controlled since performing HMBG (n=12; 63%)
- lower costs compared to glucose curves at veterinary practice (n=12; 63%)
- less stressful compared to glucose curves at veterinary practice (n=11; 58%)

Disadvantages of HMBG:

- no disadvantages (n=6; 32%)
- HMBG is time consuming (n=7; 37%)
- cat seems uncomfortable during the procedure (n=6; 32%)
- owner feeling he/she is hurting the cat (n=6; 32%)

Sampling site:

- outer pinna (n=14; 74%), outer + inner pinna (n=1; 5%)
- paw pad of the front limb (n=1; 5%), paw pad of the hind limb (n=1; 5%), paw pad of the front and hind limb (n=2; 11%)

Tools used to obtain blood samples:

 lancet (n=16; 84%), hypodermic needle (n=1; 5%), insulin needle (n=1; 5%), needle from the lancet (n=1; 5%)

Additional procedures to enhance blood sampling:

- massage the ear before puncturing it (n=12; 63%)
- apply vaseline (n=7; 37%)
- apply anaesthetic cream (e.g. EMLA) (n=5; 26%)
- clipping the ear for better visualisation of the marginal ear vein (n=2; 11%)
- using a small torch for better visualisation of the marginal ear vein (n=1; 5%)

Need for other person to assist during HBGM:

always (n=7; 37%), sometimes (n=5; 26%), never (n=7; 37%)


Recor	ding of blood glucose readings:
-	using a diary (not digital) (n=13; 68%)
-	creating tables/graphs using a computer programme/software, e.g. Microsoft Excel (n=3;
	16%)
-	using a chart supplied with the glucometer (n=2; 11%)
-	using an App for human diabetics or pets (n=1; 5%)
Diffic	ulties encountered during HMBG:
-	need for more than 1 puncture due to technical difficulties (n=17; 89%)
-	obtaining a too small blood drop (n=8; 42%)
-	difficulties using the glucometer (n=8; 42%)
-	cat resisting the sampling (n=6; 32%)
-	bruising (n=1; 5%) or formation of scar tissue (n=1; 5%) at the puncture site
How t	he difficulties with HMBG could be resolved:
-	practising the technique and the use of the glucometer (n=13; 68%)
	advice given at the re-examination at our clinic or local veterinarian (n=4; 21%)

- 411 Figure 1. DIAQoL-pet score (quality-of-life tool) in the home blood glucose monitoring (HBGM) and non-
- 412 HBGM groups over the 6 month study period. Higher scores are suggestive of better quality of life.
- 413 Circles/squares and error bars represent median and range. Significantly different values (P < 0.05) are

HBGM-group

non-HBGM-group


414 marked with an asterisk.



total DIAQoL-pet score

415


Figure 2. Average blood glucose (obtained from 24 h blood glucose curves) in the home blood glucose
monitoring (HBGM) and non-HBGM groups over the 6 month study period. Circles/squares and error bars
represent median and range. Significantly different values (P <0.05) are marked with an asterisk. Average
blood glucose was significantly lower at months 1, 3 and 6 compared with baseline in the HBGM group but not
in the non-HBGM group. There were no significant differences in average blood glucose between the groups
at any time point.



- HBGM-group
- non-HBGM-group

423

Figure 3. Serum fructosamine concentration in the home blood glucose monitoring (HBGM) and non-HBGM group over the study period. Circles/squares and error bars represent median and range. Significantly different values (P <0.05) are marked with an asterisk. Serum fructosamine concentrations were significantly lower at months 1, 3 and 6 compared with baseline in the HBGM group but not in the non-HBGM group. There were no significant differences in serum fructosamine concentrations between the groups at any time point</p>



Fructosamine